Financials data is unavailable for this security.
View more
Year on year Eagle Pharmaceuticals Inc grew revenues 84.56% from 171.55m to 316.61m while net income improved from a loss of 8.63m to a gain of 35.64m.
Gross margin | 69.84% |
---|---|
Net profit margin | 4.64% |
Operating margin | 13.98% |
Return on assets | 3.04% |
---|---|
Return on equity | 4.88% |
Return on investment | 4.04% |
More ▼
Cash flow in USDView more
In 2022, cash reserves at Eagle Pharmaceuticals Inc fell by 42.34m. However, the company earned 50.70m from its operations for a Cash Flow Margin of 16.01%. In addition the company used 86.83m on investing activities and also paid 6.21m in financing cash flows.
Cash flow per share | 2.49 |
---|---|
Price/Cash flow per share | 1.70 |
Book value per share | 19.25 |
---|---|
Tangible book value per share | 7.61 |
More ▼
Balance sheet in USDView more
Current ratio | 2.16 |
---|---|
Quick ratio | 1.67 |
Total debt/total equity | 0.2785 |
---|---|
Total debt/total capital | 0.2178 |
More ▼
Growth rates in USD
SmartText is unavailable
EPS growth(5 years) | -4.75 |
---|---|
EPS (TTM) vs TTM 1 year ago | -48.44 |